NPXe Announces the Appointment of Jim McAuliffe as Chief Financial Officer
20 August 2018
ABINGDON, UNITED KINGDOM AND BUFFALO, USA – NPXe Limited (“NeuroproteXeon” or “NPXe”), today announces the appointment of Jim McAuliffe as Chief Financial Officer with effect from 7 August 2018.
Jim is a financial leader with a wide range of experience in both the public and private sectors for the past 25 years. Prior to joining NeuroproteXeon, Jim worked at Gibraltar Industries, Uni-Select USA, Rigidized Metals Corp. and Koike Aronson/Ransome. His professional career began at PriceWaterhouse. Jim played an integral role in many complex financial transactions including registered public debt offerings, acquisition and divestiture reporting. Jim earned a BS and MBA from the University at Buffalo and a CPA from the state of New York.
Bill Burns, Chief Executive Officer at NeuroproteXeon said: “Jim is joining NeuroproteXeon at an extremely important time in the Company’s development and the wealth of experience he brings with him will be invaluable to us as we plan for future growth. I am very pleased to welcome a professional of Jim’s calibre to the leadership team and look forward to working with him.”
Commenting on his appointment Jim McAuliffe, said: “I am delighted to be joining NeuroproteXeon and am excited by the potential of its XENEX™ product to improve the survival and functional capabilities of resuscitated cardiac arrest patients. I look forward to working with Bill and the rest of the management team and Board in contributing to the Company’s future success.”
About NPXe Limited
NPXe Limited is developing XENEX™ (xenon gas for inhalation) for the treatment of Post-Cardiac Arrest Syndrome. The Company has a Special Protocol Agreement with the United States Food & Drug Administration (FDA) and A Scientific Working Party Agreement with the European Medicines Agency (EMA). Both the FDA and EMA have provided the indication with Orphan Drug status. Orphan status prolongs the period of market exclusivity post approval. Mallinckrodt has licensed the rights to market XENEX™ in North America, Australia and Japan. Linde Group has licensed the rights to market XENEX™ in the EU, United Kingdom, Norway, Switzerland and Iceland.
NeuroproteXeon Consilium (PR adviser)
Carol Burns Chris Gardner, Matthew Neal, Lindsey Neville
Communications Director firstname.lastname@example.org
Carol.email@example.com Phone: +44 (0)20 3709 5700
Phone: +1-716-332-7200 Ext 155